| Brandon Scott Sallee, | |
|
809 S Washington Ave, Emmett, ID 83617-3528 | |
| (208) 365-5341 | |
| (208) 365-5342 |
| Full Name | Brandon Scott Sallee |
|---|---|
| Gender | Male |
| Speciality | Physical Therapist |
| Location | 809 S Washington Ave, Emmett, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538891676 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| Provider Name | Peak Physical Therapy P C |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1073551560 PECOS PAC ID: 7012977168 Enrollment ID: O20041013001176 |
News Archive
Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.
In a paper appearing in Scientific Reports today, the motion of micro-organisms as they swim through various types of fluid channels show "quite strange and new" responses for single cell organisms, including the performance of somersaults, meandering wanderings, and even a ballistic type of behavior, wrote Sunghwan "Sunny" Jung, a member of the Virginia Tech Department of Biomedical Engineering and Mechanics.
Lexicon Pharmaceuticals, Inc., announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.
A team of researchers funded by the National Institutes of Health has developed a new ultrasound technique to monitor the placenta for impaired fetal blood flow early in pregnancy.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brandon Scott Sallee, 7550 W Emerald St, Boise, ID 83704-9015 Ph: () - | Brandon Scott Sallee, 809 S Washington Ave, Emmett, ID 83617-3528 Ph: (208) 365-5341 |
News Archive
Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.
In a paper appearing in Scientific Reports today, the motion of micro-organisms as they swim through various types of fluid channels show "quite strange and new" responses for single cell organisms, including the performance of somersaults, meandering wanderings, and even a ballistic type of behavior, wrote Sunghwan "Sunny" Jung, a member of the Virginia Tech Department of Biomedical Engineering and Mechanics.
Lexicon Pharmaceuticals, Inc., announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.
A team of researchers funded by the National Institutes of Health has developed a new ultrasound technique to monitor the placenta for impaired fetal blood flow early in pregnancy.
› Verified 5 days ago
Scott Glen King, M.P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 103 S Commercial Ave, Emmett, ID 83617 Phone: 208-477-8028 | |
Emme Warnken, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 809 S Washington Ave, Emmett, ID 83617 Phone: 208-365-5341 | |
Kenneth J Murdock, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 809 S Washington Ave, Emmett, ID 83617 Phone: 208-365-5341 Fax: 208-365-5343 | |
Mr. Steven Gerald Balle, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 714 N Butte Ave, Emmett, ID 83617 Phone: 208-365-4425 | |
Kathryn Margaret Phillips, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 809 S Washington Ave, Emmett, ID 83617 Phone: 208-365-5341 | |
Michelle Holt, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 809 S Washington Ave, Emmett, ID 83617 Phone: 208-365-5341 Fax: 208-365-5342 |